$ALC

The Trump administration announced MFN pricing deals with nine mid-sized pharmaceutical manufacturers, including Teva Pharmaceuticals and Sun Pharma, to lower drug costs for Medicaid. The companies committed to $19.6B in U.S. investments and ingredient donations to SAPIR. Details on discounts and exemptions from future mandates remain unclear.

Alcon has launched Precision7, a weekly contact lens, to improve patient compliance. According to the company, 80% of patients found the lens comfortable for 16 hours daily, with a 9/10 rating for vision and comfort after seven days. Illume Eyecare's Adele Jefferies noted positive initial feedback, suggesting it could be a good option for new wearers due to its simple replacement routine.

Bernstein recommends Sonova (CHF 275 PT) and Alcon (CHF 76.15 PT) as top European medtech picks for H2, citing strong growth prospects and attractive valuations. Sonova is favored for short-term gains, while Alcon is seen as a long-term compounder. Bernstein's estimates for both companies are above consensus.

Alcon has warned that a US proposal may lead companies to leave Europe. Novo Holdings and international funds are investing DKK 60 million in a new Danish biotech company, highlighting growth potential in the sector.

Bill Ackman's Pershing Square increased stakes in Visa, Mastercard, Netflix, S&P Global, Intercontinental Exchange, and Alcon, while reducing Amazon and exiting Alphabet. Ackman believes these companies will benefit from AI, citing their proprietary data and strong market positions. Pershing Square reported a -12.6% return in the first half of 2026, lagging the S&P 500. Intercontinental Exchange reported $2.7B in Q2 revenue and raised full-year guidance.

Optometrist Malik shares her experience with toric contact lenses, emphasizing patient feedback and lifestyle conversations to identify suitable candidates. She encourages practitioners to ask questions and involve the entire practice team in the process. Malik also highlights the importance of early introduction of toric lenses for better patient adaptation. Alcon's WATERINNOVATIONS toric portfolio now supports a broader range of astigmatic patients with extended parameters.

President Trump expanded drug-pricing agreements with 9 international companies, including Alcon and Teva, adding to 17 prior deals with firms like Pfizer. The MFN framework now covers 89% of the branded drug market. The impact on healthcare ETFs is mixed, with potential benefits for insurers (IHF) and uncertain effects on U.S. pharma (PPH).

President Trump secured drug pricing agreements with nine pharma firms, including Alcon, Astellas, Teva, and UCB, bringing the total to 26 firms representing 90% of the US market. The deals require Medicaid discounts and $19.6B in US manufacturing investments. The White House estimates $529B in economic savings over a decade.

Alcon (SIX/NYSE: ALC) launched UNITY M, a premium ophthalmic microscope with advanced visualization and modular upgrades. The product will begin commercial rollout in the U.S. and Japan later this year, with additional markets to follow. UNITY M is designed for surgical precision and customization, featuring a stable red reflex and color tunable illumination. The microscope has received regulatory approvals in several regions, including the U.S. and Europe.

Nine drugmakers (Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, UCB) joined Medicaid pricing deals, covering 89% of branded drug market. Savings estimated at $600B over a decade, per the White House. Medicaid copays likely unchanged. Companies to invest $19.6B in U.S. manufacturing and donate drug ingredients.